Current Report Filing (8-k)
June 04 2020 - 04:15PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 4, 2020
PDS BIOTECHNOLOGY CORPORATION
(Exact Name of Registrant as Specified in Charter)
25B Vreeland Road
Florham Park NJ 07932
(Address of Principal Executive Offices, and Zip Code)
(800) 208-3343
Registrant’s Telephone Number, Including Area Code
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of
this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
On June 4, 2020, PDS Biotechnology Corporation issued a press release announcing that The University of Texas MD Anderson Cancer Center will conduct
a phase two clinical trial of PDS0101 in combination with standard of care chemoradiotherapy for treatment of locally advanced cervical cancer.
The full text of the press release is attached hereto as Exhibit 99.1 and incorporated
herein by reference.
(d) Exhibits.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Feb 2024 to Mar 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Mar 2023 to Mar 2024